Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10.

@article{Moguen2006ComparativePA,
  title={Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10.},
  author={Karen Le Moguen and Hubert Lincet and Edwige Deslandes and Marie Hubert-Roux and C. Lange and Laurent Poulain and Pascal Gauduchon and Bruno Baudin},
  journal={Proteomics},
  year={2006},
  volume={6 19},
  pages={5183-92}
}
Ovarian cancer is one of the leading causes of mortality due to gynaecological cancer. Despite a good response to surgery and initial chemotherapy essentially based on cisplatin (cis-diamino-dichloro-platinum(II) (CDDP)) compounds, late tumour detection and frequent recurrences with chemoresistance acquisition are responsible for poor prognosis. Several mechanisms have been implicated in CDDP resistance but they are not sufficient to exhaustively explain this resistance emergence. We applied a… CONTINUE READING